--- title: "Kyverna Therapeutics (KYTX) news: class action and IPO" url: "https://aibio.space/companies/kyverna-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KYTX class action and IPO news: Kyverna faces IPO securities class action and consolidated derivative suit. Kyverna Therapeutics, Inc." --- KYTX Kyverna Therapeutics, Inc. NASDAQ · United States # Kyverna Therapeutics (KYTX) news KYTX class action and IPO news Legal · 2026-08-11 ## [Kyverna faces IPO securities class action and consolidated derivative suit](https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/) Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated. ## Latest Kyverna Therapeutics news 1. 2026-07-08 Debt Financing [Kyverna amends $150 million Oxford Finance loan facility](https://aibio.space/news/kyverna-amends-150-million-oxford-finance-loan-facility/) Kyverna extended availability of $15.0 million in remaining Term A Loans to December 31, 2026, for a $187,500 upfront fee. Further changes to the facility apply only if the company draws the full $15.0 million. 2. 2025-11-03 Debt Financing [Kyverna signs Oxford Finance loan facility of up to $150.0 million, expects to draw $25.0 million](https://aibio.space/news/kyverna-signs-oxford-finance-loan-facility-up-150-0-million-expects/) Kyverna signed a loan facility of up to $150.0 million with Oxford Finance and drew $25.0 million at closing, secured by substantially all of its assets. The company says its runway still runs into 2027, the same guidance it gave before the loan. ## Kyverna Therapeutics at a glance - **Ticker**: KYTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $199.4 million ### Related companies - [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) NASDAQ: STOK - [IN8bio](https://aibio.space/companies/in8bio/) NASDAQ: INAB - [UroGen Pharma](https://aibio.space/companies/urogen-pharma/) NASDAQ: URGN - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY - [Imunon](https://aibio.space/companies/imunon/) NASDAQ: IMNN - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL - [LeonaBio](https://aibio.space/companies/leonabio/) NASDAQ: LONA - [Apnimed](https://aibio.space/companies/apnimed/) NASDAQ: APMD ### Also on NASDAQ - [Autolus Therapeutics](https://aibio.space/companies/autolus-therapeutics/) AUTL - [NEUROONE MEDICAL TECHNOLOGIES](https://aibio.space/companies/neuroone-medical-technologies/) NMTC - [CollPlant Biotechnologies](https://aibio.space/companies/collplant-biotechnologies/) CLGN - [Pulmatrix](https://aibio.space/companies/pulmatrix/) PULM - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics-qncx/) QNCX - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA ## Kyverna Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$133.7 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | [$112.5 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | | Net income (loss) | [-$161.3 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | [-$127.5 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | | Cash from operations | [-$153.7 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | [-$114.2 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | | Cash and equivalents | [$124.1 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526344607/) | [$96.6 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | | Short-term investments | [$155.2 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526344607/) | [$189.4 million](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126242/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $31.8 million, plus short-term investments of $167.6 million, $199.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Kyverna Therapeutics Is there a class action against Kyverna Therapeutics? Our latest story on this, dated Aug 11, 2026: "Kyverna faces IPO securities class action and consolidated derivative suit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/). When did Kyverna Therapeutics go public? Our latest story on this, dated Aug 11, 2026: "Kyverna faces IPO securities class action and consolidated derivative suit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/). What is the ticker symbol of Kyverna Therapeutics? Kyverna Therapeutics, Inc. trades under the ticker KYTX on NASDAQ. Where is Kyverna Therapeutics listed? Kyverna Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Kyverna Therapeutics? The SEC Central Index Key (CIK) for Kyverna Therapeutics, Inc. is 1994702. Its filings are on SEC EDGAR. How many shares does Kyverna Therapeutics have outstanding? 61,843,444 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Kyverna Therapeutics listed under? Our directory records Kyverna Therapeutics, Inc. under United States. What does Kyverna Therapeutics do? Our directory classifies Kyverna Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Kyverna Therapeutics? The ISIN recorded for Kyverna Therapeutics, Inc. is US5019761049. Does aibio.space cover Kyverna Therapeutics? aibio.space lists Kyverna Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Kyverna Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Kyverna Therapeutics profitable? Kyverna Therapeutics, Inc. reported a net loss of $161.3 million for the fiscal year ended Dec 31, 2025, and used $153.7 million of cash in operations, per its annual report to the SEC. How much does Kyverna Therapeutics spend on research and development? $133.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Kyverna Therapeutics have? $199.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Kyverna Therapeutics (KYTX) stock news? Our latest story on Kyverna Therapeutics, dated Aug 11, 2026: "Kyverna faces IPO securities class action and consolidated derivative suit". Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated. [Source](https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/). ## Investor discussion: Kyverna Therapeutics Members talk about Kyverna Therapeutics (KYTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Kyverna Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/kytx-ex99_1.htm) 2. 2026-05-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/kytx-ex99_1.htm) 3. 2026-03-26 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126321/kytx-20260326.htm) 4. 2026-02-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/kytx-ex99_1.htm) 5. 2025-12-15 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1994702/000121390025121773/ea0269676-424b5_kyverna.htm) 6. 2025-08-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1994702/000095017025107321/kytx-20250630.htm) 7. 2025-06-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/ea024745101ex99-1_kyverna.htm) 8. 2025-04-15 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1994702/000095017025054293/kytx_424b5_prospectus.htm) 9. 2025-03-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1994702/000095017025046074/kytx-20241231.htm) 10. 2025-03-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1994702/000095017025046162/kytx_s-3_march_2025.htm) 11. 2025-01-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1994702/000095017025007220/kytx-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KYTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-KYTX/). ## SEC filings and registration - **SEC name**: Kyverna Therapeutics, Inc. - **CIK**: 1994702 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: KYTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 5980 HORTON STREET, EMERYVILLE, CA - **Phone**: 5109252492 - **Shares outstanding**: 61,843,444 as of 2026-08-03 (10-Q filed 2026-08-11) - **Former names**: Kyverna Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1994702/000119312526400062/kytx-20260924.htm) filed 2026-09-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1994702/000119312526344607/kytx-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/kytx-20260723.htm) filed 2026-07-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/kytx-20260708.htm) filed 2026-07-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/kytx-20260527.htm) filed 2026-06-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/kytx-20260514.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1994702/000119312526219397/kytx-20260331.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001994702), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Kyverna Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KYTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Kyverna Therapeutics, Inc. - **Ticker**: KYTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US5019761049 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KYTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/kyverna-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kyverna Therapeutics (KYTX) news: class action and IPO", 2026-10-31, https://aibio.space/companies/kyverna-therapeutics/